EMA Tackles Hurdles To Using Single-Arm Trial Data For Pivotal Evidence In Filings

The European Medicines Agency has highlighted issues for drug developers to consider when seeking to submit clinical data from SATs as the pivotal evidence in their marketing authorization applications instead of randomized controlled trial data.

An EMA paper discusses specific characteristics of single-arm trials • Source: Shutterstock

The choice of endpoints and sources of bias and potential mitigation are among the topics covered in a new reflection paper from the European Medicines Agency on using single-arm trials (SATs) to provide confirmatory evidence on the efficacy of an investigational drug.

Key Takeaways

The European Medicines Agency has published a reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence...

The paper will interest drug developers that want to submit clinical data from SATs as the pivotal evidence in their marketing authorization applications (MAAs) instead of randomized controlled trial (RCT)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

23 May 2025

• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

22 May 2025

• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

21 May 2025

• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

20 May 2025

• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.